Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

High-dose intravenous estrogen therapy was shown to be effective in relieving bone pain due to metastatic disease in 22 of 29 (75.9%) men with advanced hormone-resistant prostate cancer. This clinical response was accompanied by significant falls in serum prostate-specific antigen (PSA) levels in 13 (44.8%) patients. It is suggested that this clinical benefit is due to a direct inhibitory effect of estrogen on prostate cancer cells.
 ...
PMID:High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response. 247 82

For an evaluation of the clinical utility of prostate-specific antigen (PSA), 32 prostatic carcinoma patients (ages 54-76) and 13 nonprostatic carcinoma patients (ages 60-70) underwent PSA measurements and bone imaging. At the time of bone imaging, each patient's PSA value was measured by a monoclonal immunoradiometric assay. All 13 nonprostatic carcinoma patients (11 bronchogenic, 1 colon, and 1 urinary bladder) gave normal PSA values, although 6 had metastatic bone disease. The 32 prostatic cancer patients were divided into 2 groups of 16 each; PSA levels in Group 1 were abnormal (greater than or equal to ng/ml): PSA levels in Group 2 were normal (less than 4 ng/ml). In Group 1, bone images of 14 patients showed bone metastases; 6 of the 14 showed progression of metastases in a 6- to 12-month period. Two patients in Group 1 were negative for skeletal metastases. Twelve patients in Group 2 were negative for skeletal metastases; bone imaging in 1 showed regression of skeletal metastases; and 3 patients had unchanged bone lesion(s). The data indicate that PSA measurements may enhance bone imaging interpretation and provide valuable clinical monitoring of prostatic carcinoma. In the case of a patient with positive bone imaging and an unknown primary, PSA measurements may definitively determine if metastases originated from prostatic carcinoma.
 ...
PMID:Correlation of prostate-specific antigen and technetium-99m HMDP bone imaging. 247 31

We review our experience with the immunoperoxidase technique of staining tissue for prostate-specific antigen in four patients with atypical metastases from prostate cancer. Our results indicate that this test is clinically useful for the diagnosis of metastatic prostate cancer in patients with an unsuspected primary prostate malignancy. Further, application of prostatic-specific antigen testing may confirm metastatic prostate cancer in atypical sites in patients with a previously diagnosed prostate malignancy.
 ...
PMID:Atypical metastasis from prostate cancer. Clinical utility of the immunoperoxidase technique for prostate-specific antigen. 258 56

Prostate cancer is the second most common malignancy in American males and the third leading cause of cancer deaths in this population. There are no symptoms that are unique to early prostate cancer, and nearly one-half of patients will have metastatic disease at diagnosis. Because of its tremendous impact upon the health and well-being of the American male population, and the importance of early diagnosis in curability, there is keen interest in the development of effective screening procedures that are highly sensitive, specific, and cost-effective. Rectal examination serves as the historical control. The serum tumor markers of prostate cancer, prostatic acid phosphatase (PAP), and prostate-specific antigen (PSA), are sensitive but relatively nonspecific in the diagnosis of prostate cancer. The use of transrectal ultrasound as a screening tool is highly controversial but suffers from a similar lack of specificity. As yet, no diagnostic tests, alone or in combination, have proven to be of practical value in screening for prostate cancer. Fundamental but unanswered questions about the natural history and the high incidence of "latent" disease also obscure the issue of early diagnosis of prostate cancer and its impact on survival.
 ...
PMID:Early detection of prostate cancer. 266 37

Tumor-to-tumor metastases are uncommon despite the fact that the presence of two or more malignancies in a single patient is not a rare occurrence. The most frequent donor tumors are the lung, prostate, and thyroid gland, whereas renal cell carcinoma is by far the most common recipient. In this report we describe a patient dying of metastatic malignant melanoma and locally advanced prostate cancer in which the melanoma metastasized to the prostatic adenocarcinoma. The prostatic primary was well differentiated and stained positively with prostate-specific antigen and prostatic acid phosphatase, whereas the melanoma contained abundant melanin pigment and stained positively for S-100 protein. This is the second reported instance of prostatic carcinoma as the recipient in a case of tumor-to-tumor metastases and the first in the English language literature.
 ...
PMID:Malignant melanoma with metastasis to adenocarcinoma of the prostate. 291 Apr 17

Carcinomas histologically resembling nasopharyngeal lymphoepithelioma have been identified in the salivary gland, thymus, tonsil, and uterine cervix. Five patients with similar tumors primary in the skin are described. The patients ranged in age from 50 to 81 yr. Four neoplasms were situated on the head, and one was located on the shoulder. Microscopically, they were concentrated in the mid- and deep dermis and lacked connections with epidermis. The pattern was of multiple nodules, smaller irregular islands, and cords. The uniform tumor cells had moderate amounts of lightly eosinophilic cytoplasm and vesicular nuclei with one or two prominent nucleoli. A lymphoid infiltrate was intimately associated with each neoplasm and obscured the malignant epithelium in one. Neither squamous nor glandular differentiation was present, but all tumors exhibited intracytoplasmic mucin. Immunohistochemistry was positive for cytokeratin (5 of 5; diffuse) and epithelial membrane antigen (4 of 5; 3 diffuse, 1 focal). Focal reactivity was also noted for carcinoembryonic antigen (1 of 5), neuron-specific enolase (1 of 5), and vimentin (1 of 5). S100 protein, leukocyte common antigen, Factor VIII-related antigen, prostate-specific antigen (males), Leu M1, and salivary amylase reactivity were absent. One patient developed local recurrence and metastases after 39 mo and was dead of disease at 57 mo. The remaining four were free of disease after 46, 27, 25, and 6 mo of follow-up. The diagnosis of lymphoepithelioma-like carcinoma of the skin is based on microscopic findings and exclusion of occult malignancy. The tumor can be confused with a lymphoid infiltrate and is differentiated from Merkel cell carcinoma primarily on cytologic grounds. The neoplasm may be of adnexal origin.
 ...
PMID:Lymphoepithelioma-like carcinoma of the skin. 323 11

Approximately 50 per cent of patients with carcinoma of the prostate have either advanced local disease or metastases at the time of diagnosis. To achieve earlier diagnosis of prostate cancer in its localized, most treatable stages, it will be necessary to develop safe, cost-effective screening tests with sufficiently high sensitivity and specificity rates. To date, no single test fulfills these criteria, although advances in the measurement of serologic markers of prostate cancer such as prostate-specific antigen, fine-needle aspiration cytology of the prostate, and transrectal prostatic ultrasonography are being widely investigated as potential screening tests.
 ...
PMID:Early diagnosis of prostate cancer. 331 60

Thirteen cases of prostatic adenocarcinoma with endometrioid features were reviewed. The patients were older men (49-81 years) presenting with symptoms of hematuria and urinary obstruction. Each of the tumors displayed exophytic growth into the prostatic urethra, with involvement of the verumontanum. The urethral orifices of the large (primary) prostatic ducts were uniformly involved, and coexistent invasive (acinar) adenocarcinoma was identified in 10 cases (77%). The tumors exhibited a complex glandular pattern strikingly similar to uterine endometrial carcinoma, with prominent papillary formation in six cases. All cases demonstrated intense cytoplasmic immunoreactivity for prostatic acid phosphatase and prostate-specific antigen in at least part of the tumor. Focal staining for carcinoembryonic antigen was seen in three cases. Five tumors examined ultrastructurally demonstrated typical features of prostatic adenocarcinoma. Follow-up information was available on all 13 patients (6-83 months). Seven patients died of metastatic tumor (9-70 months after diagnosis), and the other six patients exhibited recurrent local or metastatic tumor. The sites of metastases were identical to those seen with invasive "acinar" prostatic adenocarcinoma, including pelvic lymph nodes, bones, and lungs. Crude 5-year survival was 15%, with a mean survival of 37 months. Adjuvant therapy provided palliative relief for many patients, but did not appear to influence survival. These findings indicate that endometrioid carcinoma is a histologically distinct variant of prostatic adenocarcinoma, with a more aggressive clinical behavior than previously thought.
 ...
PMID:Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings. 409 Nov 89

An immunoperoxidase technique for prostate-specific antigen was used to evaluate autopsy material from 8 patients with multiple prostatic metastases, 22 primary prostatic carcinomas and 12 nonprostatic tumors. All specimens of primary and metastatic prostatic carcinomas stained positively, irrespective of the Gleason grade. None of the nonprostatic tumors showed immunostaining. Thus, the method appeared to be highly specific and highly sensitive for the detection of the prostatic origin of metastases.
 ...
PMID:Prostatic origin of metastases: immunoperoxidase localization of prostate-specific antigen. 620 2

A case of prostatic carcinoid tumor with lymph node metastases is reported. The patient was a 78-year-old male who died in ventricular fibrillation. At autopsy, a 2 X 2 cm, white, irregular tumor was found in the prostate and there were several enlarged para-aortic lymph nodes. Both specimens contained a characteristic carcinoid tumor. Argyrophil stains revealed strong positivity in the primary as well as in the metastatic tumors. Electron micrographs prepared from formalin-fixed tissue demonstrated numerous membrane-bound dense-core granules. Immunoperoxidase-labeled antibodies against both prostatic acid phosphatase and prostate-specific antigen localized in the tumor cells. The ultrastructural and immunohistochemical results support differentiation of the tumor cells toward both prostatic epithelial cells and endocrine cells. We believe that this is the first reported case of a prostatic carcinoid tumor in which specific prostatic tissue markers have been demonstrated in the tumor cells.
 ...
PMID:Primary prostatic carcinoid tumor with intracytoplasmic prostatic acid phosphatase and prostate-specific antigen. 620 47


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>